Results 161 to 170 of about 15,814 (215)

Adipose-Derived Proinflammatory Visfatin Promotes Vascular Calcification via TLR4 and is Suppressed by Empagliflozin. [PDF]

Inflammation
Zhang Y, Zhao Y, Luo Y, Wang L, Liao J, Lu H, Zhang X, Ji X.   +7 more
europepmc   +1 more source

Amino acid homeostasis in the kidney: Physiological roles and pathological dysregulation

Physiological Reports, Volume 14, Issue 15, August 2026.
Abstract Amino acids are fundamental to life as protein building blocks and key regulators of metabolism and signaling. The kidney plays a critical, yet underappreciated, role in amino acid homeostasis through three interconnected pillars: selective glomerular filtration, efficient tubular reabsorption, and metabolic processing, which includes de novo ...
Shuo Liu, Caifeng Shi, Yang Zhou, Chunsun Dai   +3 more
wiley   +1 more source

SGLT2 Inhibition Attenuates Renal Tubular Senescence by Suppressing CTRP1‐Mediated Glucotoxic Stress in Diabetic Kidney Disease

The FASEB Journal, Volume 40, Issue 14, 31 July 2026.
Hyperglycemia upregulates CTRP1 and SGLT2 in renal tubular cells, promoting glucose influx, CTRP1‐mediated glucotoxic stress, and tubular senescence in diabetic kidney disease. In the experimental model, SGLT2 inhibition with dapagliflozin was associated with reduced glucose uptake, attenuation of tubular senescence, suppression of CTRP1‐related ...
Lina Gu, Buhui Liu, Lei Zhang, Jing Zhao, Weiming He, Hong Lang, Wei Sun   +6 more
wiley   +1 more source

Neuropsychiatric adverse events of SGLT2 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database. [PDF]

Front Med (Lausanne)
Yin M, Tan H, Xie S, Kuang Y, Wu Q, Ma J, Guo C.   +6 more
europepmc   +1 more source

Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status. [PDF]

Kidney Int Rep
Correa-Rotter R, Rossing P, Canziani ME, Caramori ML, Cherney D, Cronin L, Hugo C, Ji B, Meyerhoff J, Nangaku M, Silva A, Urbach D, Shah SV, de Zeeuw D, Tuttle KR.   +14 more
europepmc   +1 more source

Comparison of effectiveness and safety of bexagliflozin and other sodium-glucose cotransporter 2 inhibitors for type 2 diabetes mellitus in adults: systematic review and network meta-analysis of randomized controlled trials. [PDF]

Front Endocrinol (Lausanne)
Gao S, Zhang F, Xie X, Fan L.
europepmc   +1 more source

Dual Empagliflozin and Sacubitril/Valsartan Therapy Improves Ex Vivo Cardiac Function in a Rat Model of Heart Failure. [PDF]

Biomedicines
Murić M, Srejović I, Ravić M, Joksimović Jović J, Sretenović J, Nikolić M, Lazarević N, Andjić M, Kočović A, Bolevich S, Jakovljević V, Novaković J.   +11 more
europepmc   +1 more source

Correction: Empagliflozin attenuates dexamethasone-induced non-alcoholic steatohepatitis by regulation of ferroptosis, inflammation and autophagy. [PDF]

Front Pharmacol
Alharbi NS, Abdelmageed ME, Nader MA, Serrya MS.   +3 more
europepmc   +1 more source

Effects of empagliflozin on cardiac function and cardiorespiratory fitness in people with type 2 diabetes: a randomised controlled trial. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Nanayakkara N, Huang MLH, La Gerche A, Kaye DM, Cooper ME, Esler MD, Reutens AT, Shaw JE, Jenkins A, Cohen ND.   +9 more
europepmc   +1 more source

Comparative clinical outcomes and safety of finerenone, SGLT2 inhibitors, RAS inhibitors and ARNI in heart failure with preserved or mildly reduced ejection fraction: a systematic review and network meta-analysis. [PDF]

Front Pharmacol
Fu Z, Chen X, Liu H, Yang J, Jin T, Liu T, Ta G.   +6 more
europepmc   +1 more source